乳がんリキッドバイオプシーの世界市場レポート 2025年

乳がんリキッドバイオプシーの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR14.7％で15億6,000万米ドルに成長します。予測期間における成長の原動力は、リキッドバイオプシーアッセイの技術的進歩、早期がんスクリーニングへのリキッドバイオプシー採用の増加、リアルタイムがんモニタリング需要の高まり、プレシジョン・オンコロジーへの応用拡大、リキッドバイオプシー研究開発への投資拡大です。主な動向としては、リキッドバイオプシー解析における人工知能の統合、シングルセルシーケンスの進展、マルチオミクスリキッドバイオプシープラットフォームの開発、リキッドバイオプシーの感度と特異度の向上、超精密変異検出のためのデジタルPCRの採用などが挙げられます。

乳がん症例の増加は、今後数年間の乳がんリキッドバイオプシー市場の成長を促進すると予想されます。乳がんは乳房細胞に発生する悪性腫瘍であり、一般的には乳汁を産生する小葉や乳汁を乳首に運ぶ乳管に発生します。乳がんの有病率の増加は、遺伝的素因、ホルモンバランスの乱れ、高齢化、ライフスタイルの変化、肥満、飲酒、運動不足、放射線被曝、環境汚染物質などの要因に起因しています。乳がんリキッドバイオプシーは、血液中の循環腫瘍DNA（ctDNA）または循環腫瘍細胞（CTC）を検出し、リアルタイムでの疾患モニタリングを可能にすることにより、治療において重要な役割を果たしています。治療効果の評価、治療抵抗性の検出、標的治療のための遺伝子変異の同定に役立ちます。例えば、がん研究、教育、アドボカシー、患者支援を目的とする米国の非営利団体である米国がん協会によると、乳がんの新規患者数は2024年の31万3,510人から2025年には31万9,750人に増加すると予測されています。その結果、乳がん罹患率の増加が乳がんリキッドバイオプシー市場の拡大に拍車をかけています。

乳がんリキッドバイオプシー市場の主要企業は、コンパニオン診断薬などの革新的な市場開拓に注力しており、特定の治療法が最も有効な患者を特定することで個別化治療を促進しています。コンパニオン診断薬は、リキッドバイオプシー技術を活用して、遺伝子変異、循環腫瘍DNA（ctDNA）、治療反応性を示すタンパク質発現などのバイオマーカーを検出します。例えば、2023年1月、米国のバイオテクノロジー企業であるGuardant Health Inc.は、同社のGuardant360 CDxリキッドバイオプシー検査が、ESR1遺伝子変異を有する進行性または転移性乳がん患者に対する治療薬であるMenarini GroupのORSERDU（エラセストラント）のコンパニオン診断薬として食品医薬品局（FDA）の承認を取得しました。今回の承認により、がん専門医は本検査を用いて包括的なゲノム・プロファイリングを実施することが可能となり、標的治療が有効な患者を特定することができるようになります。また、ガーダント・ヘルス社にとって、乳がんに対する初のFDA承認となり、プレシジョン・オンコロジーにおける同社の存在感を高めることになります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界乳がんリキッドバイオプシーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の乳がんリキッドバイオプシー市場：成長率分析
• 世界の乳がんリキッドバイオプシー市場の実績：規模と成長, 2019-2024
• 世界の乳がんリキッドバイオプシー市場の予測：規模と成長, 2024-2029, 2034F
• 世界乳がんリキッドバイオプシー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の乳がんリキッドバイオプシー市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 消耗品
• キット
• 世界の乳がんリキッドバイオプシー市場バイオマーカー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 細胞外小胞（EV）
• 遊離DNA（cfDNA）
• 循環腫瘍RNA（ctRNA）
• 循環腫瘍細胞（CTC）
• 遊離RNA（cfRNA）
• その他のバイオマーカー
• 世界の乳がんリキッドバイオプシー市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 早期発見またはスクリーニング
• 診断
• その他の用途
• 世界の乳がんリキッドバイオプシー市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 研究所
• 病院
• 医師の検査室
• リファレンスラボ
• 公衆衛生研究所
• 調査機関
• 小分子研究所
• 病理学研究所
• 世界の乳がんリキッドバイオプシー市場消耗品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 試薬
• ポリメラーゼ連鎖反応（PCR）アッセイ
• シーケンシングパネル
• サンプル収集チューブ
• 世界の乳がんリキッドバイオプシー市場キットの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• DNAベースの液体生検キット
• RNAベースの液体生検キット
• マルチマーカー液体生検キット

第7章 地域別・国別分析

• 世界の乳がんリキッドバイオプシー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の乳がんリキッドバイオプシー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 乳がんリキッドバイオプシー市場：競合情勢
• 乳がんリキッドバイオプシー市場：企業プロファイル
  • Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • Roche Diagnostics Overview, Products and Services, Strategy and Financial Analysis
  • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
  • Siemens Healthineers Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Agilent Technologies Inc.
• Illumina Inc.
• Sysmex Corporation
• Qiagen N.V.
• Myriad Genetics Inc.
• NeoGenomics Laboratories
• Guardant Health Inc.
• Twist Bioscience
• Foundation Medicine Inc.
• Biodesix Inc.
• Menarini Silicon Biosystems
• Datar Cancer Genetics
• Abcam plc
• OncoDNA SA
• Genomic Health Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 乳がんリキッドバイオプシー市場2029：新たな機会を提供する国
• 乳がんリキッドバイオプシー市場2029：新たな機会を提供するセグメント
• 乳がんリキッドバイオプシー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A breast cancer liquid biopsy is a minimally invasive test that detects and analyzes tumor-derived materials in a patient's blood or other bodily fluids, offering valuable insights into the presence, progression, and genetic profile of breast cancer without the need for a traditional tissue biopsy.

The primary products used in breast cancer liquid biopsy include consumables and kits. Consumables refer to disposable materials, reagents, and kits utilized in liquid biopsy tests to detect and analyze biomarkers associated with breast cancer. The key biomarkers include extracellular vesicles (EVs), cell-free DNA (cfDNA), circulating tumor RNA (ctRNA), circulating tumor cells (CTCs), cell-free RNA (cfRNA), and others. These biomarkers are applied in early detection or screening, diagnosis, and other purposes. The end users of breast cancer liquid biopsy encompass laboratories, hospitals, physician laboratories, reference laboratories, public health laboratories, research institutes, small molecular laboratories, and pathology laboratories.

The breast cancer liquid biopsy market research report is one of a series of new reports from The Business Research Company that provides breast cancer liquid biopsy market statistics, including breast cancer liquid biopsy industry global market size, regional shares, competitors with a breast cancer liquid biopsy market share, detailed breast cancer liquid biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer liquid biopsy industry. This breast cancer liquid biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The breast cancer liquid biopsy market size has grown rapidly in recent years. It will grow from $0.78 billion in 2024 to $0.90 billion in 2025 at a compound annual growth rate (CAGR) of 15.0%. The growth during the historic period can be attributed to advancements in next-generation sequencing (NGS), the increasing prevalence of breast cancer, the growing demand for non-invasive diagnostic methods, the rising adoption of personalized medicine, and increased funding for cancer research.

The breast cancer liquid biopsy market size is expected to see rapid growth in the next few years. It will grow to $1.56 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The projected growth in the forecast period is driven by technological advancements in liquid biopsy assays, increasing adoption of liquid biopsy for early cancer screening, rising demand for real-time cancer monitoring, expanding applications in precision oncology, and growing investments in liquid biopsy research and development. Key trends include the integration of artificial intelligence in liquid biopsy analysis, advancements in single-cell sequencing, the development of multi-omics liquid biopsy platforms, improvements in liquid biopsy sensitivity and specificity, and the adoption of digital PCR for ultra-precise mutation detection.

The rising number of breast cancer cases is expected to drive the growth of the breast cancer liquid biopsy market in the coming years. Breast cancer is a malignancy that originates in the breast cells, typically in the milk-producing lobules or the ducts that transport milk to the nipple. The increasing prevalence of breast cancer is attributed to factors such as genetic predisposition, hormonal imbalances, an aging population, lifestyle changes, obesity, alcohol consumption, physical inactivity, radiation exposure, and environmental pollutants. Breast cancer liquid biopsy plays a crucial role in treatment by detecting circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the blood, enabling real-time disease monitoring. It helps assess treatment response, detect therapy resistance, and identify genetic mutations for targeted therapies. For example, according to the American Cancer Society, a US-based nonprofit organization dedicated to cancer research, education, advocacy, and patient support, new breast cancer cases are projected to increase from 313,510 in 2024 to 319,750 in 2025. As a result, the growing incidence of breast cancer is fueling the expansion of the breast cancer liquid biopsy market.

Leading companies in the breast cancer liquid biopsy market are focusing on innovative developments, such as companion diagnostics, to facilitate personalized treatment by identifying patients who are most likely to benefit from specific therapies. Companion diagnostics leverage liquid biopsy technology to detect biomarkers, including genetic mutations, circulating tumor DNA (ctDNA), and protein expressions that indicate treatment responsiveness. For instance, in January 2023, Guardant Health Inc., a US-based biotechnology company, received Food and Drug Administration (FDA) approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Menarini Group's ORSERDU (elacestrant), a therapy for advanced or metastatic breast cancer patients with ESR1 mutations. This approval allows oncologists to conduct comprehensive genomic profiling using the test, enabling them to identify patients who may benefit from targeted therapy. It also marks Guardant Health's first FDA approval for breast cancer, strengthening its presence in precision oncology.

In January 2024, Guardant Health Inc. partnered with Hikma Pharmaceuticals plc to enhance early cancer detection, monitor recurrence, and optimize treatment selection using Guardant Health's advanced liquid and tissue biopsy technologies. This collaboration strengthens Guardant Health's global presence and addresses the increasing cancer burden in the Middle East and North Africa. Hikma Pharmaceuticals plc is a UK-based pharmaceutical company specializing in innovative healthcare solutions.

Major players in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc.

North America was the largest region in the breast cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in breast cancer liquid biopsy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the breast cancer liquid biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The breast cancer liquid biopsy market consists of revenues earned by entities by providing services such as early cancer detection, treatment monitoring, minimal residual disease (MRD) detection, recurrence prediction, and genetic mutation analysis for targeted therapy selection. The market value includes the value of related goods sold by the service provider or included within the service offering. The breast cancer liquid biopsy market also includes sales of circulating tumor DNA (ctDNA) assay kits, circulating tumor cell (CTC) detection systems, next-generation sequencing (NGS) panels, PCR-based liquid biopsy tests, blood collection tubes, and consumables and reagents used for non-invasive cancer diagnostics and monitoring. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Breast Cancer Liquid Biopsy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on breast cancer liquid biopsy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for breast cancer liquid biopsy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The breast cancer liquid biopsy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Consumables; Kits
• 2) By Biomarkers: Extracellular Vesicles (EVs); Cell-free DNA (cfDNA); Circulating Tumor RNA (ctRNA); Circulating Tumor Cells (CTCs); Cell-free RNA (cfRNA); Other Biomarkers
• 3) By Application: Early Detection Or Screening; Diagnosis; Other Applications
• 4) By End Users: Laboratories; Hospitals; Physician Laboratories; Reference Laboratories; Public Health Laboratories; Research Institutes; Small Molecular Laboratories; Pathology Laboratories
• Subsegments:
• 1) By Consumables: Reagents; Polymerase Chain Reaction (PCR) Assays; Sequencing Panels; Sample Collection Tubes
• 2) By Kits: DNA-based Liquid Biopsy Kits; RNA-based Liquid Biopsy Kits; Multi-marker Liquid Biopsy Kits
• Companies Mentioned: Johnson & Johnson Private Limited; Roche Diagnostics; Merck KGaA; Thermo Fisher Scientific; Siemens Healthineers
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Breast Cancer Liquid Biopsy Market Characteristics

3. Breast Cancer Liquid Biopsy Market Trends And Strategies

4. Breast Cancer Liquid Biopsy Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Breast Cancer Liquid Biopsy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Breast Cancer Liquid Biopsy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Breast Cancer Liquid Biopsy Market Growth Rate Analysis
• 5.4. Global Breast Cancer Liquid Biopsy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Breast Cancer Liquid Biopsy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Breast Cancer Liquid Biopsy Total Addressable Market (TAM)

6. Breast Cancer Liquid Biopsy Market Segmentation

• 6.1. Global Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Consumables
• Kits
• 6.2. Global Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Extracellular Vesicles (EVs)
• Cell-free DNA (cfDNA)
• Circulating Tumor RNA (ctRNA)
• Circulating Tumor Cells (CTCs)
• Cell-free RNA (cfRNA)
• Other Biomarkers
• 6.3. Global Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early Detection Or Screening
• Diagnosis
• Other Applications
• 6.4. Global Breast Cancer Liquid Biopsy Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Laboratories
• Hospitals
• Physician Laboratories
• Reference Laboratories
• Public Health Laboratories
• Research Institutes
• Small Molecular Laboratories
• Pathology Laboratories
• 6.5. Global Breast Cancer Liquid Biopsy Market, Sub-Segmentation Of Consumables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Reagents
• Polymerase Chain Reaction (PCR) Assays
• Sequencing Panels
• Sample Collection Tubes
• 6.6. Global Breast Cancer Liquid Biopsy Market, Sub-Segmentation Of Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• DNA-based Liquid Biopsy Kits
• RNA-based Liquid Biopsy Kits
• Multi-marker Liquid Biopsy Kits

7. Breast Cancer Liquid Biopsy Market Regional And Country Analysis

• 7.1. Global Breast Cancer Liquid Biopsy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Breast Cancer Liquid Biopsy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Breast Cancer Liquid Biopsy Market

• 8.1. Asia-Pacific Breast Cancer Liquid Biopsy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Breast Cancer Liquid Biopsy Market

• 9.1. China Breast Cancer Liquid Biopsy Market Overview
• 9.2. China Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Breast Cancer Liquid Biopsy Market

• 10.1. India Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Breast Cancer Liquid Biopsy Market

• 11.1. Japan Breast Cancer Liquid Biopsy Market Overview
• 11.2. Japan Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Breast Cancer Liquid Biopsy Market

• 12.1. Australia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Breast Cancer Liquid Biopsy Market

• 13.1. Indonesia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Breast Cancer Liquid Biopsy Market

• 14.1. South Korea Breast Cancer Liquid Biopsy Market Overview
• 14.2. South Korea Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Breast Cancer Liquid Biopsy Market

• 15.1. Western Europe Breast Cancer Liquid Biopsy Market Overview
• 15.2. Western Europe Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Breast Cancer Liquid Biopsy Market

• 16.1. UK Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Breast Cancer Liquid Biopsy Market

• 17.1. Germany Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Breast Cancer Liquid Biopsy Market

• 18.1. France Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Breast Cancer Liquid Biopsy Market

• 19.1. Italy Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Breast Cancer Liquid Biopsy Market

• 20.1. Spain Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Breast Cancer Liquid Biopsy Market

• 21.1. Eastern Europe Breast Cancer Liquid Biopsy Market Overview
• 21.2. Eastern Europe Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Breast Cancer Liquid Biopsy Market

• 22.1. Russia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Breast Cancer Liquid Biopsy Market

• 23.1. North America Breast Cancer Liquid Biopsy Market Overview
• 23.2. North America Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Breast Cancer Liquid Biopsy Market

• 24.1. USA Breast Cancer Liquid Biopsy Market Overview
• 24.2. USA Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Breast Cancer Liquid Biopsy Market

• 25.1. Canada Breast Cancer Liquid Biopsy Market Overview
• 25.2. Canada Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Breast Cancer Liquid Biopsy Market

• 26.1. South America Breast Cancer Liquid Biopsy Market Overview
• 26.2. South America Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Breast Cancer Liquid Biopsy Market

• 27.1. Brazil Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Breast Cancer Liquid Biopsy Market

• 28.1. Middle East Breast Cancer Liquid Biopsy Market Overview
• 28.2. Middle East Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Breast Cancer Liquid Biopsy Market

• 29.1. Africa Breast Cancer Liquid Biopsy Market Overview
• 29.2. Africa Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Breast Cancer Liquid Biopsy Market Competitive Landscape And Company Profiles

• 30.1. Breast Cancer Liquid Biopsy Market Competitive Landscape
• 30.2. Breast Cancer Liquid Biopsy Market Company Profiles
  • 30.2.1. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Diagnostics Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Siemens Healthineers Overview, Products and Services, Strategy and Financial Analysis

31. Breast Cancer Liquid Biopsy Market Other Major And Innovative Companies

• 31.1. Agilent Technologies Inc.
• 31.2. Illumina Inc.
• 31.3. Sysmex Corporation
• 31.4. Qiagen N.V.
• 31.5. Myriad Genetics Inc.
• 31.6. NeoGenomics Laboratories
• 31.7. Guardant Health Inc.
• 31.8. Twist Bioscience
• 31.9. Foundation Medicine Inc.
• 31.10. Biodesix Inc.
• 31.11. Menarini Silicon Biosystems
• 31.12. Datar Cancer Genetics
• 31.13. Abcam plc
• 31.14. OncoDNA SA
• 31.15. Genomic Health Inc.

32. Global Breast Cancer Liquid Biopsy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Breast Cancer Liquid Biopsy Market

34. Recent Developments In The Breast Cancer Liquid Biopsy Market

35. Breast Cancer Liquid Biopsy Market High Potential Countries, Segments and Strategies

• 35.1 Breast Cancer Liquid Biopsy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Breast Cancer Liquid Biopsy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Breast Cancer Liquid Biopsy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer